Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio MEDIA RELEASE Afqlir®...
Sandoz reports third-quarter and nine-month 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE...
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position Ad hoc announcement pursuant to art. 53...
Sandoz reports second-quarter sales and half-year 2024 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA...
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Ad hoc announcement pursuant to art. 53...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Ad hoc announcement pursuant to art. 53 SIX Swiss...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement...
Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of...
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Ad hoc announcement pursuant to art...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering Ad hoc announcement pursuant to...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines MEDIA RELEASE EUR 50m...
Sandoz reports fourth quarter 2023 sales and full-year 2023 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA...
Sandoz receives FDA approval for first and only denosumab biosimilars MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz...
Sandoz announces nominations to the Board of Directors and leadership change Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.